Evotec (EVO) Competitors $3.64 +0.10 (+2.82%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$3.78 +0.14 (+3.71%) As of 08/22/2025 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVO vs. ABVX, MRUS, CYTK, VKTX, TGTX, KRYS, ACAD, PCVX, AAPG, and ACLXShould you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Abivax (ABVX), Merus (MRUS), Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry. Evotec vs. Its Competitors Abivax Merus Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Vaxcyte Ascentage Pharma Group International Arcellx Abivax (NASDAQ:ABVX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Is ABVX or EVO more profitable? Abivax has a net margin of 0.00% compared to Evotec's net margin of -20.14%. Abivax's return on equity of 0.00% beat Evotec's return on equity.Company Net Margins Return on Equity Return on Assets AbivaxN/A N/A N/A Evotec -20.14%-16.94%-8.14% Do analysts prefer ABVX or EVO? Abivax currently has a consensus target price of $92.33, indicating a potential upside of 19.48%. Evotec has a consensus target price of $5.40, indicating a potential upside of 48.35%. Given Evotec's higher probable upside, analysts clearly believe Evotec is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Evotec 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation and earnings, ABVX or EVO? Abivax has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbivaxN/AN/A-$190.71MN/AN/AEvotec$862.40M1.50-$212.18MN/AN/A Do insiders & institutionals believe in ABVX or EVO? 47.9% of Abivax shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, ABVX or EVO? Abivax has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Does the media refer more to ABVX or EVO? In the previous week, Abivax and Abivax both had 5 articles in the media. Abivax's average media sentiment score of 1.30 beat Evotec's score of -0.09 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAbivax beats Evotec on 9 of the 13 factors compared between the two stocks. Get Evotec News Delivered to You Automatically Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVO vs. The Competition Export to ExcelMetricEvotecMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$2.54B$5.83B$9.78BDividend YieldN/A1.67%4.40%4.05%P/E RatioN/A5.4322.8124.74Price / Sales1.50752.08473.17122.93Price / CashN/A179.1038.0259.36Price / Book1.355.939.536.60Net Income-$212.18M$31.83M$3.26B$265.65M7 Day Performance-3.19%1.89%2.14%2.02%1 Month Performance-4.71%1.33%2.81%-0.32%1 Year Performance8.66%8.84%30.70%19.06% Evotec Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOEvotec1.5414 of 5 stars$3.64+2.8%$5.40+48.4%+17.8%$1.29B$862.40M0.004,827ABVXAbivax2.9061 of 5 stars$70.01-0.6%$92.33+31.9%+562.8%$5.32BN/A0.0061Positive NewsShort Interest ↑MRUSMerus2.2624 of 5 stars$66.00-1.9%$88.50+34.1%+26.5%$5.09B$36.13M-12.0037News CoveragePositive NewsCYTKCytokinetics3.7202 of 5 stars$38.95+0.7%$71.58+83.8%-31.8%$4.63B$18.47M-7.64250News CoverageVKTXViking Therapeutics3.9956 of 5 stars$42.09+5.1%$86.92+106.5%-59.6%$4.50BN/A-27.5120Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3409 of 5 stars$27.73-1.2%$46.25+66.8%+20.7%$4.46B$329M74.95290Positive NewsKRYSKrystal Biotech4.7224 of 5 stars$146.30-2.6%$210.75+44.1%-23.8%$4.35B$290.52M29.74210Trending NewsAnalyst ForecastACADACADIA Pharmaceuticals3.8457 of 5 stars$25.06-1.1%$28.88+15.2%+64.2%$4.27B$957.80M18.84510Positive NewsInsider TradePCVXVaxcyte2.4578 of 5 stars$32.09-1.9%$136.50+325.4%-58.7%$4.25BN/A-7.81160News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$47.49+5.6%N/AN/A$4.18B$134.35M0.00600News CoverageACLXArcellx2.1244 of 5 stars$71.82-3.1%$114.31+59.2%+7.3%$4.11B$107.94M-21.0080Positive News Related Companies and Tools Related Companies Abivax Alternatives Merus Alternatives Cytokinetics Alternatives Viking Therapeutics Alternatives TG Therapeutics Alternatives Krystal Biotech Alternatives ACADIA Pharmaceuticals Alternatives Vaxcyte Alternatives Ascentage Pharma Group International Alternatives Arcellx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evotec AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Evotec With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access